Kinyua A, Turner L, Kimingi H, Mwai K, Mwikali K, Andisi C
J Infect. 2024; 89(4):106252.
PMID: 39182654
PMC: 11409615.
DOI: 10.1016/j.jinf.2024.106252.
Mardani A, Hezarjaribi H, Fakhar M, Emadi S, Rezaei-Rad A, Butore J
Ann Med Surg (Lond). 2018; 34:34-38.
PMID: 30191063
PMC: 6125797.
DOI: 10.1016/j.amsu.2018.08.016.
Mukap M, Sprod C, Tefuarani N, Laman M, Page-Sharp M, Salman S
Antimicrob Agents Chemother. 2018; 62(10).
PMID: 30012775
PMC: 6153847.
DOI: 10.1128/AAC.00940-18.
Weaver R, Reiling L, Feng G, Drew D, Mueller I, Siba P
Sci Rep. 2016; 6:33094.
PMID: 27604417
PMC: 5015043.
DOI: 10.1038/srep33094.
Dinko B, King E, Targett G, Sutherland C
Parasite Immunol. 2016; 38(6):352-64.
PMID: 27084060
PMC: 5089589.
DOI: 10.1111/pim.12323.
Validation and Application of a Dried Blood Spot Ceftriaxone Assay.
Page-Sharp M, Nunn T, Salman S, Moore B, Batty K, Davis T
Antimicrob Agents Chemother. 2015; 60(1):14-23.
PMID: 26438505
PMC: 4704204.
DOI: 10.1128/AAC.01740-15.
Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates.
Chan J, Fowkes F, Beeson J
Cell Mol Life Sci. 2014; 71(19):3633-57.
PMID: 24691798
PMC: 4160571.
DOI: 10.1007/s00018-014-1614-3.
The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria.
Reiling L, Richards J, Fowkes F, Wilson D, Chokejindachai W, Barry A
PLoS One. 2012; 7(9):e45253.
PMID: 23028883
PMC: 3447948.
DOI: 10.1371/journal.pone.0045253.
Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity.
Chan J, Howell K, Reiling L, Ataide R, Mackintosh C, Fowkes F
J Clin Invest. 2012; 122(9):3227-38.
PMID: 22850879
PMC: 3428085.
DOI: 10.1172/JCI62182.
Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.
Wilson D, Fowkes F, Gilson P, Elliott S, Tavul L, Michon P
PLoS One. 2011; 6(11):e27705.
PMID: 22110733
PMC: 3217002.
DOI: 10.1371/journal.pone.0027705.
Intermittent preventive treatment to reduce the burden of malaria in children: new evidence on integration and delivery.
Beeson J, Rogerson S, Mueller I, Richards J, Fowkes F
PLoS Med. 2011; 8(2):e1000410.
PMID: 21304919
PMC: 3032544.
DOI: 10.1371/journal.pmed.1000410.
Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development.
Boyle M, Wilson D, Richards J, Riglar D, Tetteh K, Conway D
Proc Natl Acad Sci U S A. 2010; 107(32):14378-83.
PMID: 20660744
PMC: 2922570.
DOI: 10.1073/pnas.1009198107.
Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays.
Wilson D, Crabb B, Beeson J
Malar J. 2010; 9:152.
PMID: 20525251
PMC: 2891815.
DOI: 10.1186/1475-2875-9-152.
Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.
McCallum F, Persson K, Mugyenyi C, Fowkes F, Simpson J, Richards J
PLoS One. 2008; 3(10):e3571.
PMID: 18958278
PMC: 2570221.
DOI: 10.1371/journal.pone.0003571.
